Introduction The healthcare situation of multiple sclerosis (MS) and its course are not being
thoroughly investigated in Japan. We aimed to examine the current healthcare situation …

Objective To assist policymakers as they reflect on treatment protocols and approaches for
the efficient delivery of medical care for multiple sclerosis (MS) patients in Japan. Methods …

Background In this study, we aimed to understand the trends in total and itemized medical
expenses, especially of disease-modifying therapy (DMT), for multiple sclerosis (MS) in …

Objectives Disease‐modifying treatments (DMT s) constitute the largest direct medical cost
for multiple sclerosis (MS). This study aims at investigating predictors of the 10‐year …

Background. Cohort studies and registries provide opportunities to estimate long‐term
outcome in multiple sclerosis. Objectives. To describe changes in disability (EDSS), relapse …

Objective To understand, through an analysis of health insurance claims data, the current
treatment status and medical cost of multiple sclerosis (MS) in Japan. Methods We analyzed …

Multiple sclerosis (MS) is uncommon in China and the standard of care is underdeveloped,
with limited utilization of disease-modifying treatment (DMT). An understanding of real-world …

Objective To assess the disease burden and health economics of inpatients with multiple
sclerosis (MS) in China by evaluating the direct, indirect, and intangible costs. Methods A …

Background Estimating multiple sclerosis (MS) prevalence and incidence, and assessing
the utilisation of disease-modifying therapies (DMTs) and healthcare resources over time is …

Background The epidemiology of multiple sclerosis (MS) is important for planning disease
modifying therapy (DMT). Secular changes in the use of DMT in MS can guide future service …